Tuesday, April 16, 2024

Key Aids in Effective Smoking Cessation, Nicotine and Varenicline Confirmed in IQWiG Study

Similar articles

The Institute for Quality and Efficiency in Health Care (IQWiG) has conducted a comprehensive evaluation of four drugs approved for the treatment of severe tobacco addiction, focusing on their efficacy in smoking cessation. This assessment is critical in light of new legal regulations in Germany, allowing smokers with severe addiction to receive medication as part of evidence-based programs covered by statutory health insurance.

Key Findings of the IQWiG Assessment

  1. Drugs Evaluated: The study evaluated bupropion, cytisine, nicotine, and varenicline, including their combinations, against no drug therapy for tobacco dependence.
  2. Effective Active Ingredients: The assessment revealed clear benefits for two of the drugs: nicotine and varenicline. Smokers using these medications, in addition to supportive non-drug methods, were significantly more likely to quit smoking six months post-treatment compared to those receiving no additional drug therapy.
  3. Consideration of Side Effects: While side effects such as sleep disorders, headaches, fatigue, nausea, or skin irritation were noted, they did not outweigh the overall benefits of nicotine and varenicline in aiding smoking cessation.
  4. Subgroup Analyses: The effectiveness of these drugs for long-term smoking cessation was not influenced by the severity of tobacco addiction, challenging the demarcation of the population with severe tobacco dependence as defined in the law.
  5. Insufficient Data for Other Drugs: There was a lack of data regarding the benefits of bupropion, cytisine, or their combinations, partly due to the non-submission of data by manufacturers. Hence, no definitive conclusions could be drawn about their efficacy.
  6. Advantages of Varenicline: Varenicline showed a higher likelihood of smoking cessation at six and twelve months compared to non-drug therapy. Despite neuropsychiatric and other side effects, its benefits in smoking cessation were not undermined.
  7. Nicotine as an Effective Aid: Nicotine also proved effective, with higher smoke-free rates after six and twelve months of therapy. The side effects of nicotine did not diminish its advantage in aiding smoking cessation.
  8. No Impact of Tobacco Dependence Severity: The severity of tobacco dependence did not appear to influence the effectiveness of nicotine or varenicline.
  9. Overall Assessment: IQWiG concluded that both nicotine and varenicline offer a greater benefit compared to no drug therapy for smoking cessation. The clear advantages of these drugs in aiding smoking cessation, despite their side effects, make them viable options for severely addicted smokers.

Smoking Cessation

A Crucial Guide for Effective Smoking Cessation Treatment

In summary, the IQWiG’s evaluation highlights the effectiveness of nicotine and varenicline in treating severe tobacco dependence, providing a significant benefit in smoking cessation efforts. While the assessment recognizes the occurrence of side effects, these do not override the overall advantages of these drugs. The findings are pivotal for healthcare providers and patients in selecting effective treatments for smoking cessation, especially for those grappling with severe tobacco addiction.

 

Resource: IQWiG, January 09, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article